AlphAIAlphAI — Financial news for AI agents
investing.com$PODD

Jefferies raises Insulet stock price target to $200 on strong results

Jefferies raised its price target on Insulet (PODD) to $200 from $190, citing strong Q3 2026 results. Sales grew 19.6% to $842M, beating estimates, with EPS of $1.99. The company raised full-year sales guidance to 21-22% growth. TD Cowen also raised its target to $163, maintaining a Hold rating.

Original reporting
investing.com
Published Nov 4, 2026, 9:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 9:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$PODD
Bullish
high confidence
Mentioned
$PODD
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$PODDBullishMed
01

Why it matters

The earnings beat and higher guidance underpin the price‑target increase, indicating strong momentum.

02

Market read

The upgrade may drive buying in Insulet and related diabetes‑care stocks.

03

What to watch

Potential supply‑chain constraints or regulatory changes could temper growth.

Relevance 7/10Novelty 7/10Timing: post‑earnings today

Background

Insulet reported 19.6% revenue growth and a 60% EPS beat, raising full‑year guidance and prompting analyst upgrades.

Company-level read

Ticker impact

$PODDBullishHigh confidence
Context

Jefferies raised its price target on Insulet to $200 after the company posted Q3 2026 earnings that beat revenue and EPS expectations.

Expected impact

likely upward pressure as investors price in the higher target.

Evidence & confidence

The price target increase reflects confidence in Insulet's growth and margins, which can attract buying.

Market effects

Sector

Boosts sentiment for the diabetes‑device sector and may lift peers.

Regional

Positive for U.S. healthcare stocks in the near term.

Global

Limited to investors focused on medical‑device and biotech equities.

Counterpoint

What could challenge this read

The target raise may be premature if future guidance softens or competition intensifies.

Key entities

  • company
    Insulet Corporation

    Medical‑device maker of the Omnipod insulin‑pump system.

  • analyst
    Jefferies

    Investment bank that raised the price target to $200.

Read at source← All news

StoryInsulet beats Q3 expectations and raises 2026 revenue-growth guidance

Also covered by

5 outlets

Related articles

$PODDMedAI 8/10

Insulet Corp (PODD) Q3 2026 Earnings Call Highlights: Revenue Up 19%, EPS Jumps 60%

Insulet Corp (PODD) reported Q3 2026 revenue up 19% and EPS up 60%. US new customer starts were flat, while global growth was low single-digits. The company expects 2027 growth to be modestly below mid-teens due to tougher comparisons and increased competition. Free cash flow for 2026 is expected to be $275 million. PBM negotiations for 2027 are ongoing, creating some uncertainty. The company plans to launch Omnipod 6 in 2027, with features aimed at improving clinical outcomes and lifestyle fit.

finance.yahoo.com
$PODDHighAI 8/10

What Insulet (PODD) Said on Its Q3 Earnings Call

Insulet (PODD) reported Q3 revenue of $842M, adjusted EPS of $1.99, and record gross margin of 74.2%. The company narrowed its 2026 revenue outlook to 21-22% growth and expects 2027 growth to be modestly below mid-teens. Insulet also announced a $1B increase to its share repurchase program and product updates, including Omnipod 6 and a type 2 diabetes system.

finance.yahoo.com
Med

Insulet Corporation Q3 2026 Earnings Call Summary

Insulet Corporation reported a 20% increase in its global customer base for Q3 2026, driven by growth in the Type 2 segment and international expansion. The company launched Omnipod Discover and plans Omnipod 6 for 2027, expecting growth to moderate to below mid-teens. Management approved a $1 billion share repurchase increase and anticipates stable pricing and retention. According to the company, new competitive entrants and a larger revenue base influence the conservative 2027 outlook.

finance.yahoo.com
$PODDMedAI 8/10

Insulet (PODD) Q3 2026 Earnings Call Transcript

Insulet (PODD) reported Q3 2026 revenue of $842.0M, up 19.6% in constant currency, exceeding guidance. Adjusted EPS rose 59.9% to $1.99. The company grew its global customer base to over 600,000, with US Omnipod revenue up 14.7% and international up 33.0%. Management expects 2027 growth to moderate due to competition and difficult comparisons. The board approved a $1B increase in share repurchase authorization, with $400M planned for Q4.

fool.com
$PODDHighAI 8/10

Insulet Q3 Net Income Rises; Issues FY26 Outlook

Insulet (PODD) reported Q3 net income of $141.1M, up from $87.6M YoY, with revenue at $842.0M, a 19.2% increase. Adjusted EPS rose 59.9% to $1.99. The company raised FY26 revenue growth guidance to 21-22% from 20-22%. Shares fell 4.43% in pre-market trading.

rttnews.com